AstraZeneca

SCRS launches Global Impact Partnership Program

Friday, June 21, 2013 10:35 AM

The Society for Clinical Research Sites (SCRS) has launched the Global Impact Partnership (GIP) Program. In just over one month, 12 organizations have joined as partners to provide ongoing development, feedback and support of industry initiatives designed to include and improve the voice of clinical research sites. 

More... »

AstraZeneca selects Cambridge, U.K. for R&D center and corporate headquarters

Thursday, June 20, 2013 11:00 AM

AstraZeneca is building a new $514 million global R&D center and corporate headquarters on the Cambridge Biomedical Campus. By 2016, the new site will house 2,000 employees.

More... »

AstraZeneca acquires Pearl Therapeutics

Tuesday, June 11, 2013 01:02 PM

AstraZeneca has acquired Pearl Therapeutics, a privately held company focused on the development of inhaled small-molecule therapeutics for respiratory disease.

More... »

AstraZeneca awarded grant by The Michael J. Fox Foundation

Thursday, May 30, 2013 03:50 PM

The Michael J. Fox Foundation for Parkinson's Research (MJFF) awarded global biopharmaceutical AstraZeneca (AZ) a grant to support research on levodopa-induced dyskinesias (LID), a complication of therapies commonly used to reduce Parkinson's disease symptoms.

More... »

AstraZeneca to acquire Omthera, NDA-ready novel dyslipidemia treatment

Wednesday, May 29, 2013 11:35 AM

Global biopharmaceutical company, AstraZeneca, has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, N.J., focused on the development and commercialization of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia.

More... »

AltheRx raises $15M, names Jim Bennethum CEO, appoints new board of directors

Monday, May 6, 2013 10:41 AM

AltheRx Pharmaceuticals, a privately-held clinical development company, announced a restructuring that includes a $15 million financing, the appointment of Jim Bennethum as CEO, and the appointment of a new board of directors.

More... »

BIND Therapeutics, AstraZeneca ink cancer nanomedicine agreement

Monday, April 22, 2013 03:17 PM

BIND Therapeutics, a clinical-stage biopharmaceutical company, and AstraZeneca have entered into a strategic collaboration to develop and commercialize an Accurin, a targeted and programmable cancer nanomedicine from BIND's medicinal nanoengineering platform, based on a molecularly targeted kinase inhibitor developed and owned by AstraZeneca.

More... »

Horizon Discovery, AstraZeneca collaborate on oncology drug discovery

Monday, April 22, 2013 01:54 PM

Horizon Discovery, a provider of research tools to support translational genomics research, and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon's first-in-class kinase target program, HD-001, as a means of developing novel therapies for multiple cancer types.

More... »

AstraZeneca touts top-line results from OSKIRA-1 phase III study of fostamatinib in RA

Friday, April 5, 2013 12:33 PM

AstraZeneca released top-line results of OSKIRA-1, a phase III study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA). OSKIRA-1 had two primary endpoints: assessing signs and symptoms of RA as measured by ACR20 response rates, and an X-ray endpoint known as mTSS (modified Total Sharp Score).

More... »

MedImmune aquires Alphacore Pharma

Wednesday, April 3, 2013 02:20 PM

MedImmune, AstraZeneca’s global biologics R&D arm, has acquired AlphaCore Pharma, an Ann Arbor, Mich.-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme.

More... »